Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: A case report and review of the literature. Issue 52 (December 2016)

• Record Type: Journal Article
• Authors: Liu, Junru; Li, Juan; Chen, Meilan; Kuang, Lifen
• Editors: Rosenthal., Ken S.
• Is Part Of: Medicine. Volume 95:Issue 52(2016)
• Page Start: e5760
• Publication Date: 2016-12
• Subjects: autologous stem cell transplantation -- Bortezomib -- proteasome inhibitor -- rheumatoid arthritis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000005760
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale and Patients concerns: Despite the introduction of varied disease-modifying antirheumatic drugs and biological agents, a substantial proportion of patients remain untreatable. We report a 56-year-old Chinese female patient with a case of refractory rheumatoid arthritis (RA) complicated with multiple myeloma (MM) who was treated successfully with Bortezomib followed by autologous stem cell transplantation (ASCT). Diagnosis and Interventions: We report a 56-year-old Chinese female patient who was diagnosed as RA complicating with MM. She received 4 cycles of Bortezomib-based chemotherapy followed by ASCT. The response of her RA and MM were evaluated after every cycle of Bortezomib-based chemotherapy. Interventions and Outcomes: After the first Bortezomib-based chemotherapy cycle, this patient's symptoms were significantly alleviated and thereafter the RA activity continued to improve. After the 4 courses of Bortezomib-based chemotherapy, the C-reactive protein was <0.5 mg/dL and the disease activity score 28-erythrocyte sedimentation rate was 2.0. No hematological or nonhematological side effects were observed during the treatment of Bortezomib. Lessons: Bortezomib might be a new safe and promising drug for refractory RA patients.